Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maria Nachury

Showing results (1-10 of 96) with videos related to

Pageof 10
Sort By:
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|November 19, 2022
ReplyAnthony Buisson, Maria Nachury, Mathurin Fumery
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|October 6, 2023
Switching From Intravenous to Subcutaneous Infliximab is Safe and Feasible in Patients With Inflammatory Bowel Disease Suffering From Obesity: A Post Hoc Analysis of the REMSWITCH StudyAnthony Buisson, Maria Nachury, Bruno Pereira, et al.
European Journal of Gastroenterology & Hepatology|September 4, 2023
Alternative to subtotal colectomy for pregnant woman with medically refractory acute severe ulcerative colitisCaroline Valibouze, Maria Nachury, Sofia Hambli, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|March 21, 2022
Efficacy of Induction Therapy With Calcineurin Inhibitors in Combination With Ustekinumab for Acute Severe Ulcerative ColitisPauline Veyrard, Gauthier Pellet, David Laharie, et al.
Therapeutic Advances in Gastroenterology|March 28, 2025
Switching from intravenous to subcutaneous infliximab is safe and feasible in patients with perianal Crohn's diseasePauline Wils, Mathurin Fumery, Maria Nachury, et al.
Inflammatory Bowel Diseases|January 10, 2023
Fecal Mucin O-Glycans as Novel Biomarkers in Inflammatory Bowel DiseasesCatherine Robbe Masselot, Camille Cordier, Benjamin Marsac, et al.
Inflammatory Bowel Diseases|November 25, 2022
Human Fecal Mucin Glycosylation as a New Biomarker in Inflammatory Bowel DiseasesCatherine Robbe Masselot, Camille Cordier, Benjamin Marsac, et al.
Joint Bone Spine|February 4, 2019
Vedolizumab has no efficacy on articular manifestations in patients with spondyloarthritis associated with inflammatory bowel diseaseJulien Paccou, Maria Nachury, Cédric Duchemin, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|May 29, 2023
Effectiveness and safety of tofacitinib in patients with chronic pouchitis multirefractory to biologicsMathieu Uzzan, Maria Nachury, Aurélien Amiot, et al.
The American Journal of Gastroenterology|April 7, 2025
A Risk Stratification Tool for Relapse After Intravenous-To-Subcutaneous Switching of Infliximab in Patients With Inflammatory Bowel DiseasesYannick Hoffert, Zhigang Wang, Mathurin Fumery, et al.
Pageof 10

Showing results (1-10 of 96) with videos related to

Sort By:
Pageof 10
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|November 19, 2022
ReplyAnthony Buisson, Maria Nachury, Mathurin Fumery
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|October 6, 2023
Switching From Intravenous to Subcutaneous Infliximab is Safe and Feasible in Patients With Inflammatory Bowel Disease Suffering From Obesity: A Post Hoc Analysis of the REMSWITCH StudyAnthony Buisson, Maria Nachury, Bruno Pereira, et al.
European Journal of Gastroenterology & Hepatology|September 4, 2023
Alternative to subtotal colectomy for pregnant woman with medically refractory acute severe ulcerative colitisCaroline Valibouze, Maria Nachury, Sofia Hambli, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|March 21, 2022
Efficacy of Induction Therapy With Calcineurin Inhibitors in Combination With Ustekinumab for Acute Severe Ulcerative ColitisPauline Veyrard, Gauthier Pellet, David Laharie, et al.
Therapeutic Advances in Gastroenterology|March 28, 2025
Switching from intravenous to subcutaneous infliximab is safe and feasible in patients with perianal Crohn's diseasePauline Wils, Mathurin Fumery, Maria Nachury, et al.
Inflammatory Bowel Diseases|January 10, 2023
Fecal Mucin O-Glycans as Novel Biomarkers in Inflammatory Bowel DiseasesCatherine Robbe Masselot, Camille Cordier, Benjamin Marsac, et al.
Inflammatory Bowel Diseases|November 25, 2022
Human Fecal Mucin Glycosylation as a New Biomarker in Inflammatory Bowel DiseasesCatherine Robbe Masselot, Camille Cordier, Benjamin Marsac, et al.
Joint Bone Spine|February 4, 2019
Vedolizumab has no efficacy on articular manifestations in patients with spondyloarthritis associated with inflammatory bowel diseaseJulien Paccou, Maria Nachury, Cédric Duchemin, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|May 29, 2023
Effectiveness and safety of tofacitinib in patients with chronic pouchitis multirefractory to biologicsMathieu Uzzan, Maria Nachury, Aurélien Amiot, et al.
The American Journal of Gastroenterology|April 7, 2025
A Risk Stratification Tool for Relapse After Intravenous-To-Subcutaneous Switching of Infliximab in Patients With Inflammatory Bowel DiseasesYannick Hoffert, Zhigang Wang, Mathurin Fumery, et al.
Pageof 10